GlassScriptPhysician profile
Parker G Lavigne
NPI 1467816595
$1,835.28
in general payments reported to CMS, 2019-2025
24 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.97 · 2021: $278 · 2022: $48.27 · 2023: $629 · 2024: $335 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $333.11 | 2023-2025 | |
| Abbott Laboratories | $295.63 | 2023-2025 | Cardiomems, Merlin@Home, Xience Skypoint |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.23 | 2020-2025 | Lifevest |
| Bardy Diagnostics, INC. | $125.00 | 2021 | |
| Impulse Dynamics (USA) INC. | $117.28 | 2023 | Optimizer |
| Cleerly, INC. | $116.93 | 2023 | Cleerly Labs |
| Abiomed | $85.01 | 2023-2025 | Impella |
| Medtronic, INC. | $72.05 | 2025 | Symplicity G3 |
| Boston Scientific Corporation | $69.63 | 2024-2025 | Watchman, Watchman Flx |
| Zoll Circulation INC | $48.27 | 2022 | |
| Atricure, INC. | $46.97 | 2024 | |
| Amgen INC. | $36.65 | 2023-2025 | Repatha |
| Angiodynamics, INC. | $26.40 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.40 | 2025 | Uptravi |
| Lexicon Pharmaceuticals, INC. | $21.95 | 2023 | Inpefa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.26 | 2025 | Zepbound, Mounjaro |
| C. R. Bard, INC. & Subsidiaries | $17.28 | 2025 | Purewick Female External Catheter |
| E.R. Squibb & Sons, L.L.C. | $17.22 | 2024 | Eliquis |
| Pfizer INC. | $16.75 | 2025 | |
| Scpharmaceuticals INC. | $16.21 | 2025 | |
| Chiesi USA, INC. | $15.77 | 2021 | |
| Merck Sharp & Dohme LLC | $15.61 | 2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $14.67 | 2025 | |
| Silk Road Medical, INC. | $14.00 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parker Lavigne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.